TY - JOUR
T1 - Recent advances and future directions in mantle cell lymphoma research
T2 - report of the 2016 mantle cell lymphoma consortium workshop
AU - Kahl, Brad S.
AU - Dreyling, Martin
AU - Gordon, Leo I.
AU - Quintanilla-Martinez, Leticia
AU - Sotomayor, Eduardo M.
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/7/3
Y1 - 2017/7/3
N2 - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1. Although MCL is associated with clinical heterogeneity, outcomes are generally poor and no standard treatment has been established. However, the recent approval of ibrutinib provides a new therapeutic option. Moreover, recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients. Multiple novel strategies are being evaluated in the treatment of MCL, including both targeted agents and cellular immunotherapies. At the Lymphoma Research Foundation’s 12th MCL Workshop, researchers gathered to discuss research findings, clinical trial results, and future directions related to MCL, its biology, and its treatment. This manuscript, which includes a summary of each presentation, aims to review recent findings in MCL research and highlight potential areas for future study.
AB - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1. Although MCL is associated with clinical heterogeneity, outcomes are generally poor and no standard treatment has been established. However, the recent approval of ibrutinib provides a new therapeutic option. Moreover, recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients. Multiple novel strategies are being evaluated in the treatment of MCL, including both targeted agents and cellular immunotherapies. At the Lymphoma Research Foundation’s 12th MCL Workshop, researchers gathered to discuss research findings, clinical trial results, and future directions related to MCL, its biology, and its treatment. This manuscript, which includes a summary of each presentation, aims to review recent findings in MCL research and highlight potential areas for future study.
KW - Lymphoma and Hodgkin’s disease
KW - clinical results
KW - immunotherapy
KW - marrow and stem cell transplantation
KW - pharmacotherapeutics
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85011270569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011270569&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1283036
DO - 10.1080/10428194.2017.1283036
M3 - Review article
C2 - 28140709
AN - SCOPUS:85011270569
SN - 1042-8194
VL - 58
SP - 1561
EP - 1569
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -
